Epstein-barr virus detection in nasopharyngeal carcinoma-implications in a low-risk area  by Breda, Eduardo et al.
310
Brazilian Journal of otorhinolaryngology 76 (3) May/June 2010
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Epstein-barr virus detection in nasopharyngeal carcinoma - 
implications in a low-risk area
Abstract
Eduardo Breda 1, Raquel Jorge Ferreira Catarino 2, Isabel Azevedo 3, Marisa Lobão 4, Eurico Monteiro 5, Rui 
Medeiros 6 
1 MD, ENT.
2 MSc, Researcher, Microbiologist.
3 MD, Oncologist.
4 MD, Radiologist.
5 MD, ENT.
6 PhD, Researcher, Pharmacist.
Instituto Português de Oncologia Francisco Gentil do Porto, EPE.
Send correspondence to: Eduardo Breda - MD Instituto Português de Oncologia, Porto, Serviço de Otorrinolaringologia - R. Dr. Ant. Bernardino Almeida, 4200-072 Porto, Portugal.
Tel: 351-22 5084000 - E-mail: erbreda@gmail.com
Paper submitted to the BJORL-SGP (Publishing Management System – Brazilian Journal of Otorhinolaryngology) on March 25, 2009; 
and accepted on April 29, 2010, 2010. cod. 6324
Several studies have been published concerning Epstein-barr virus (EBV) infection and 
nasopharyngeal cancer (NPC) development. The incidences of histological types are different 
according to endemic or non-endemic regions. Latent EBV infection is found in almost all cases of 
NPC in endemic regions, but normally absent in type I carcinomas, more common in non-endemic 
regions. 
Aim: The purpose of this hospital-based study was to analyze the presence of EBV in nasopharyngeal 
tumor tissues and in peripheral blood of nasopharyngeal cancer patients and healthy individuals, 
in a low risk, non-endemic area. 
Methods: EBV detection in samples of nasopharyngeal cancer patients and healthy individuals. 
Results: This study indicates that the frequency of EBV positive cases in peripheral blood is higher 
in advanced tumor stages. 
Conclusions: The incidence rates of NPC have a distinct distribution. Since the prevalence of this 
disease is low in occidental countries, little is known about the biology of these tumors in non-
endemic areas. We observed statistically significant differences in EBV detection between the NPC 
patient group and the control group. This study may help to understand the biological mechanisms 
of NPC and the correlation of EBV infection with this disease, in a low risk, non-endemic region. 
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INTRODUCTION
The nasopharyngeal carcinoma (NPC) has different 
geographic and ethnic distribution when compared to 
other head and neck tumors. In 2000 there were 64,798 
cases reported throughout the world and over 80% of 
these came from Asian countries, especially China and 
other southeastern Asian countries1. Globally speaking it 
is a rare disease, with an incidence below 1/100,000 in 
Caucasian individuals from North America and Western 
countries. The highest incidence is found in Southern 
China (25-30/100,000 individuals per year), especially in 
Canton.
NPC is a different type of head and neck cancrum. 
The World Health Organization (WHO) considers three 
histological types of NPC based on differentiation grade. 
Type I concerns keratinizing epidermoid carcinomas; 
Type II are the non-keratinizing and Type III are the un-
differentiated carcinomas, also called lymphoepitheliomas 
- characterized by a prominent lymphocytic infiltrate. This 
interaction between tumor cells and lymphocytes seems 
crucial for the continuous spread of the Type III2 malignant 
carcinoma components. Of these, variants II and III are 
the most frequent and have common etiological charac-
teristics, associated with the Epstein - Barr virus (EBV) 
infection. First described by Epstein and Barr in 19643, the 
EBV is a Gamma Herpes virus of the lymphocryptovirus 
genus, taxonomically called Human Herpes Virus 4, and 
man is its natural and only host.
The primary infection is usually acquired during 
childhood and 95% of the adults have the virus in their 
latent form within the host’s B cells. The virus is the 
agent responsible for infectious mononucleosis and its 
associations with the Burkitt Lymphoma and NPC are well 
known4. The endemicity rate for the Epstein-Barr virus 
varies according to the geographic region investigated, 
being very high in Northern Africa (Algeria and Tunisia) 
and China, and very low in Northern Europe (Denmark 
and Holland)5.
Nasopharyngeal tumors are made up of neoplastic 
cells derived from the non-keratinized epithelium with an 
inflammatory infiltrate in the stroma and have a bad prog-
nosis among malignant head and neck tumors. Studies in 
the literature show that the EBV infection in nasopharyn-
geal epithelial cells happen before clonal expansion of 
the tumor cells population6. Studies in normal nasopha-
ryngeal tissues and on biopsies of pre-malignant tissues 
show the presence of genetic alterations at an early stage 
of carcinogenesis, indicating that the stable infection of 
EBV epithelial cells requires a changed cell environment5.
Many studies have been published concerning the 
association between EBV infection and nasopharyngeal 
carcinogenesis development7. The prevalence of histology 
types are different comparing endemic and non-endemic 
regions. In endemic areas, Type III represents over 97% 
of the cases, while the keratinizing type is more com-
mon in western countries (~75%)2. Beyond histological 
differences, the latent infection by the Epstein-Barr virus 
is present in almost all NPC cases in endemic regions, 
but it is usually not present in Type I carcinomas - more 
common in non-endemic regions8.
A hospital-based study previously published by our 
group showed that contrary to what has been published 
by other western countries, the prevalence of Types II 
and III in Northern Portugal was higher than in the other 
groups, with 93.75% of non-keratinizing carcinomas and 
only 6.25% of keratinizing carcinomas, in a total of 350 
patients analyzed9.
The objective of the present study was to detect 
the Epstein-Barr virus in nasopharyngeal tumor tissue 
and peripheral blood from patients with nasopharyngeal 
carcinoma and healthy individuals coming from a non-
endemic low-risk area.
MATERIALS AND METHODS
 
Patient selection
We reviewed the cases of nasopharyngeal carci-
noma that came to the ENT Department of our Institute.
We studied 43 cases with fragments included in 
paraffin blocks, from which we found EBV in 19 cases 
of undifferentiated carcinoma of the nasopharynx (10 
men and 9 women) (ages between 13 and 86 years). 
We also included in the study 17 nasopharyngeal tumor 
tissue biopsies and samples of the peripheral blood from 
32 patients with undifferentiated carcinoma of the naso-
pharynx (ages between 20 and 71 years) and 45 samples 
from the blood donors without known oncologic disease 
with ages between 18 and 64 years).
 
DNA extraction and purification
The viral DNA in the paraffin bloc samples was 
extracted by means of an enzymatic digestion using 200ml 
of digestion buffer (TrisHCL 10mM, KCl 50mM, MgCl2 
2.5mM, 0.5% Tween 20). The tubes were incubated du-
ring the night at 37°C, and the lysis was interrupted by 
incubation at 95°C during 10 min. The DNA obtained was 
purified by the phenol-chloroform method and resuspen-
ded in 50ml of bi-distilled water. The samples were frozen 
at -20°C for later use.
In regards of the peripheral blood samples, we 
collected 5ml of peripheral blood from each patient into 
a tube with EDTA in order to isolate the plasma. The 
samples were centrifuged at 1600 x g and the plasma was 
carefully removed from the EDTA tubes and transferred 
to polypropylene tubes. They were stored at -20°C until 
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processed. The plasma DNA samples were extracted by 
means of the Qiagen Blood mini kit (Qiagen). The pro-
tocol utilized followed the steps recommended by the 
manufacturer. We used 200 µL of plasma to extract the 
DNA through columns.
DNA extraction from nasopharyngeal biopsy sam-
ples was carried out from fresh tissue, using the QIAamp 
Tissue Kit (Qiagen), following the protocol recommended 
by the manufacturer.
EBV was analyzed in the tumoral tissue from 
samples in paraffin blocks. Viral DNA amplification was 
carried out through the PCR nested method using the 
following primers (DE 5’ to 3’): E3-44mer: GCGGGTG-
GAGGGAAAGG; E5-25mer: GTCAGCCAAGGGACGCG; 
E3-2PCR: GCCACCTGGCAGCCCTAAAG and E5-2PCR: 
AGGCTGCCCACCCTGAGGAT. The E3-44mer and E5-
25mer primers were utilized in the first PCR reaction, 
being followed by another PCR reaction with the E3-2PCR 
and E5-2PCR primers, and the final product weighed 
184pb. The PCR reactions were used in a programmable 
thermocycler (Biometra), bringing to each PCR tube 2ml 
of DNA to the following mixture: buffer 1X, 1.5mM of 
MgCl2, 0.2mM of dNTPs, 0.5mM of each primer and 1U 
of Taq polymerase. The first PCR reaction conditions were 
as follows: initial denaturation at 94°C during 5min; 40 
cycles of 30s at 94°C; 30s at 57°C and 1min at 72°C, and 
one step of final extension of 7min at 72°C. Two ml of 
the product from the first reaction were subjected to a 
second PCR. The second reaction parameters were iden-
tical to those of the first one, except for the annealing 
temperature, which went from 57°C to 50°C. We did an 
agarose gel electrophoresis at 3% (w/v) dyed in ethidium 
bromide and studied under ultraviolet light.
 
EBV analysis in the tumoral tissue of biopsies and peri-
pheral blood
EBV detection in the fresh tissue and peripheral 
blood samples was carried out through the PCR tech-
nology in real time. The PCR primers were selected in 
a way as to pair them to the BALF5 region of the viral 
genome which codes the viral polymerase DNA. The 
forward and reverse primer sequences were, respectively: 
5’- CGGAAGCCCTCTGGACTTC- 3’ and 5’- CCCTGTTTA-
TCCGATGGAATG - 3’. A fluorogenic probe was used 
(VIC5’- TGTACACGCACGAGAAATGCGCC - 3’TAMRA) 
with a sequence between the PCR primers, synthesized 
by PE Applied Biosystems (Foster city, Calif.). The PCR 
reaction was done using the PCR Taq-Man (PE Applied 
Biosystems) kit. In short: 2.5 µL of DNA extraction solu-
tion from 200 µL of plasma added to a PCR mixture with 
de plasma 10 mM of Tris (pH 8.3), 50 mM of KCl, 10 mM 
of EDTA, 5 mM of MgCl2, 100 µM of dATP, dCTP, dGTP 
and dTTP, 0.2 µM of each primer, 0.1 µM of the probe 
and 1.25 U of AmpliTaq Gold (PE Applied Biosystems). 
Amplification followed, starting with a 50°C cycle during 
2min., AmpliTaq Gold activation during 10 min. at 95°C, 
47 cycles of 15 sec. at 95°C and 1 minute at 62°C. The 
entire process was done by an ABIPRISM 7300 (PE Applied 
Biosystems) sequence detector.
 
DNA Quality Control
We did the PCR for the β-globin gene sequence 
aiming at confirming the presence of an amplifiable DNA. 
The target sequence was a 110pb segment and we used 
the following primers (from 5’ to 3’): PCO3: ACACAAC-
TGTGTTCACTAGC; PCO4: CAACTTCATCCACGTTCACC. 
The protocol included forty 20s cycles at 95°C, 45s at 55°C 
and 45s at 75°C.
 
Statistical analysis
The statistical analysis of the results was done using 
the SPSS (vs. 15.0) statistical software. Differences among 
mean values were calculated using the t-Student test. The 
Chi-Squared test was used to compare the frequencies of 
the categorical variables. A value of p<0.05 was considered 
statistically significant.
RESULTS
The sample description in the group of cases with 
nasopharyngeal carcinoma (NPC) and in the control 
group is depicted on Table 1. In the group of cases with 
nasopharyngeal carcinoma we used the samples extracted 
from the nasopharyngeal tumoral tissue in paraffin blocks 
and the fresh tissue and peripheral blood of diseased 
individuals. In the control group, made up of individuals 
without known oncologic disease, we used samples from 
the peripheral blood. We studied a total of 68 individuals 
with NPC and 45 healthy controls. Among the cases, 19 
samples came from tumoral tissue in paraffin blocks (mean 
age of 56.6 years, standard deviation of 11.4), 17 samples 
from fresh tissue (mean age of 51.8 years, 7.4 of standard 
deviation) and 32 samples from peripheral blood (mean 
age of 48.1 years, standard deviation of 11.3) from NPC 
patients. The mean age of control group individuals was 
51.8 years (standard deviation of 7.4). The frequencies of 
males and females were: 73.5% and 26.5%, respectively in 
the group of individuals with NPC and 60.0% and 40.0%, 
respectively in the control group.
The frequency of positive EBV cases in the tumoral 
tissue samples in paraffin blocks was 84.2%. The results 
of EBV detection in the fresh tissue samples showed a 
100% rate of positive cases, corroborating other studies 
published which show that all the nasopharyngeal tumor 
cells had viral DNA10, 11. In the cases of samples from 
the peripheral blood of NPC patients we found 53.1% of 
positive EBV cases. In the control group we did not find 
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EBV DNA in the peripheral blood of healthy individuals 
(Table 2). We found statistically significant differences in 
the positive and negative EBV cases in the control group 
and in the group of patients with NPC (P<0.001) in all 
types of samples analyzed; Table 2).
Table 3 depicts the results from comparing the EBV 
positive and negative cases insofar as the gender of pa-
tients with NPC and controls were concerned. We did not 
find statistically significant differences in the distribution 
of positive and negative EBV cases as to the gender of the 
groups analyzed. The analysis of EBV detection according 
to tumor stage (Table 4) indicates that the frequency of 
positive EBV cases is higher in more advanced tumors, 
despite the fact that such difference is in the very threshold 
of statistical significance (P=0.069).
Table 1. Sample description in the group of cases of nasopharyngeal carcinoma of the nasopharynx and in the control group.
 Patients with Nasopharyngeal Carcinoma Control Group
 Type of sample
 Paraffin blocs Fresh tissue biopsy Periphery blood  Peripheral blood
Number of cases 17 32 45
Mean age ± standard deviation 56.6 ± 11.4 51.8 ± 7.4 48.1 ± 11.3 51.8 ± 7.4
Gender     
Males 10 (52.6%) 13 (76.5 %) 27 (84.4%) 27 (60.0%)
Females 9 (27.4%) 4 (23.5 %) 5 (15.6%) 18 (40.0%)
Table 2. EBV detection result in the control group and in the group of patients with nasopharyngeal carcinoma according to the type of sample.
 EBV detection p value*
 Positive (%) Negative (%)
Control group    
Peripheral blood (n=45) 0 (0.0) 45 (100.0) -
Nasopharyngeal carcinoma cases    
Paraffin blocks (n=19) 16 (84.2) 3 (15.8) <0.0001
Fresh tissue biopsy (n=17) 17 (100.0) 0 (0.0) <0.0001
Peripheral blood (n=32) 17 (53.1) 15 (46.9) <0.0001
Total (n=68) 50 (73.5) 18 (26.5) <0.0001
*Chi-squared test
Table 3. Comparison of the positive and negative EBV results frequencies concerning the gender of patients with nasopharyngeal carcinoma 
and control group.
 EBV Detection p value*
 Males Females
 Positive (%) Negative (%) Positive (%) Negative (%)
Nasopharyngeal carcinoma cases
Paraffin blocks (n=19) 9 (90.0) 1 (10.0) 7 (77.7) 2 (22.3) 0.466
Fresh tissue - biopsy (n=17) 13 (100.0) 0 (0.0) 4 (100.0) 0 (0.0) -
Peripheral blood (n=32) 13 (48.1) 14 (51.9) 4 (80.0) 1 (20.0) 0.190
Total (n=68) 35 (70.0) 15 (30.0) 15 (83.3) 3 (16.7) 0.272
Control Group      
Peripheral blood (n=45) 0 (0.0) 27 (100.0) 0 (0.0) 18 (100.0) -
* Chi-square test
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DISCUSSION
The frequency of positive EBV cases in the tumor 
tissue samples in paraffin blocks was of 84.2%. Although 
the frequency of EBV positive cases is high, one could 
expect that all tissues would have EBV infected cells. This 
result is probably due to the DNA quality of the samples 
and efficacy of viral DNA extraction based on the sam-
ples of tumoral tissue fragments in paraffin blocks. Given 
the insufficient quality of the samples we used a nested 
PCR protocol, in an attempt to enhance the detection 
method sensitivity. In fact, the EBV detection results from 
the fresh tissue samples showed 100% of positive cases, 
corroborating other studies published which show that 
all the nasopharyngeal tumor cells had viral DNA10, 11. In 
the case of samples from the peripheral blood in patients 
with NPC we found 53.1% of positive EBV cases. In the 
control group we did not find EBV DNA in the peripheral 
blood of the healthy individuals.
These results indicate a higher frequency of positive 
EBV cases among patients with NPC and such differen-
ce was statistically significant, regardless of the type of 
sample analyzed (P<0.001 for the paraffin block samples, 
fresh tissue and peripheral blood).
Recent studies indicate that patients with naso-
pharyngeal carcinoma have EBV DNA circulating in their 
peripheral blood12-14. The EBV detection analysis matched 
tumor stage (Table 4), indicating that the frequency 
of EBV-positive cases is higher in more advance stage 
tumors, although this difference is in the threshold of 
statistical significance (P=0.069). These results indicate 
that the most advanced tumors seem to release EBV DNA 
more easily or in greater quantity to the peripheral blood 
of diseased people.
EBV DNA was detected in all the samples from 
biopsies of nasopharyngeal fresh tumoral tissue, indi-
cating that the PCR real-time protocol used is sensitive 
and indicated to detect EBV. The EBV detection analysis 
in the peripheral blood has been investigated in recent 
studies in order to assess the clinical implications of the 
EBV presence in the peripheral circulating blood from 
patients with nasopharyngeal carcinoma. This study indi-
cates that the frequency of EBV-positive cases detected in 
the peripheral blood is higher in advanced studies. These 
results can serve as basis for future studies designed to 
assess the test value as an additional tumoral marker for 
diagnostic purposes. On the other hand, with the sup-
port of quantitative tests aiming at quantifying the levels 
of EBV in the blood of NPC patients, we will be able to 
assess the virus levels value as a prognostic marker in 
these patients. These tests seem to have a high medical 
value given the sensitiveness of the method and the ease 
of sampling, in which the only thing that is needed is to 
collect peripheral blood, a non-invasive technique, with 
a potential for clinical applicability.
The rates of nasopharyngeal carcinoma have a dis-
tinct distribution in ethnical and geographic terms. Given 
its low incidence in western countries, very little is known 
about the biology of these tumors in non-endemic areas, 
knowing that most of the studies are based in high risk 
population, with their own characteristics, which may 
not necessarily be the same seen in other countries. The 
unequal prevalence of these tumors throughout the world 
suggests a complex etiology associated with genetic and 
environmental factors, and both risk factors seem to be 
different in their geographic distribution, both in terms 
of environmental distribution and genetic background. 
Prior studies indicate that EBV needs a changed genetic 
environment in order to promote cell prolipheration7. The 
genetic profile can then alter the individual’s susceptibility 
to cell immortalization by the virus, thus modulating the 
impact of the EBV effects on the carcinogenesis of these 
tumors.
CONCLUSIONS
These results indicate that there are differences in 
the Epstein-Barr virus study in the group of patients with 
NPC and in the control group without tumor.
This study can help understand the biological 
mechanisms in the nasopharyngeal tumor and in the 
correlation of these tumors with the EBV infection in a 
non-endemic, low risk area.
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